Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto.
The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significa